Chronic Pancreatitis, Pancreatic Cancer
Conditions
Brief summary
Pain is a major clinical problem for many patients with pancreatic cancer and chronic pancreatitis (CP).In pancreatic cancer, nearly 75% of patients suffer from pain at the time of diagnosis, with over 90% of patients in advanced stages. In CP, pain occurs in 80-90% of patients and strongly affects quality of life. For both conditions, the majority of pain is addressed using the WHO analgesic ladder. However, more invasive pain therapies are often necessary. Currently, in several centers in the Netherlands, treatment with IV lidocaine is already used in clinical practice in patients with pancreatic cancer and CP. Based on practical experience, the majority of patients benefit from this therapy, however, its efficacy in terms of duration of pain relief, decrease in pain scores, increase in patient satisfaction and adverse events is unknown. Therefore, the aim of this study is to investigate the efficacy of monitored single intravenous infusion in patients with pancreatic cancer and CP.
Interventions
DRUGLidocaine IV
Administration of IV lidocaine will take place according to the standard protocol as is currently already used in daily clinical practice. First, a lidocaine bolus of 1.5mg/kg is administered, followed by a continuous infusion of 1.5mg/kg/hour. When no pain relief is noticed, each 15 minutes the dose is raised with 1ml up to a maximum of 2mg/kg/hour. If again no pain relief is noticed, the anesthesiologist is consulted. When the anesthesiologist agrees, and no side effects occur, lidocaine infusion can be increased up to a maximum of 2.5mg/kg/hour, with a maximum of 250mg/hour. When there is a pain response - pain is reduced with at least two NRS points or 30% from baseline - that dose is administered for two hours continuously. Following treatment the patient will be observed for an hour before leaving the hospital or recovery unit, again, all according to current daily clinical practice.
Sponsors
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Age 18 years or older; * NRS score ≥4 despite previous pain treatment with non-opioid analgesics, opioids or TCAs. Or pain treatment with non-opioid analgesics, opioids or TCAs with adequate effect on pain, but unable to reduce the opioids; * For CP: * Diagnosis of CP based on the M-ANNHEIM diagnostic criteria;17 * For pancreatic cancer: * Diagnosis of pancreatic cancer (all stages) * Eastern Cooperative Oncology Group (ECOG) performance status 0-2; * Life expectancy ≥ 3 months; * Consensus of surgeon/gastroenterologist and anesthesiologist for suitability for treatment
Exclusion criteria
* Patients with contra-indications for intravenous lidocaine i.e. medical history of non-adequate liver function, hypersensitivity to local anesthetics, New York Heart Association Class III or IV cardiac disease or myocardial infarction within the past 12 months, shock, and conduction abnormalities (defined as second and third degree atrioventricular (AV) blocks, or atrial fibrillation); * Patients who underwent invasive pain therapies: such as endoscopic treatment or surgery for chronic pancreatitis, and splanchnic nerves or coeliac plexus blocks, neurolysis, or PRF for pancreatic cancer.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pain score | Directly after treatment | Assessed by the Brief Pain inventory (scale: 0-10, higher score indicate worse outcome) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pain score | Directly after treatment, two weeks, and after one-three-six months | Assessed by the Numeric Rating Scale (scale: 0-10, higher score indicate worse outcome) |
| Pain score long term | After two weeks, and one-three-six months | Assessed by the Brief Pain inventory (scale: 0-10, higher score indicate worse outcome) |
| Quality of life (SF-12) | Baseline, and after one-three-six months | Assessed by the SF-12 (scale: 0-100: higher scores indicate better quality of life) |
| Effect of treatment | After two weeks, and one-three-six months | Assed by the Global Perceived effect (scale: 0-7, higher score indicate better outcome) |
| Number of total performed treatments with intravenous lidocaine per participant | During follow-up (six months) | — |
| Numer of participants with minor or major complications | During follow-up (six months) | — |
| Dose reduction of opioids | During follow-up (six months) | — |
| Dose of intravenous lidocaine administered | During intervention | in mg/kg |
Countries
Netherlands
Outcome results
None listed